Patent · US Active

Oxidation-resistant AAT gene therapy

US12031144B2 · kind B2 · utility

0Cited by

5References

19Claims

0Family size

Assignee

Cornell University · IT

Inventors

Ronald G. Crystal · Potomac, US
Katie Stiles · The Bronx, US
Meredith Sosulski · New York, US
Stephen Kaminsky · The Bronx, US
Dolan Sondhi · New York, US
Bishnu De · New Hyde Park, US
Jonathan B. Rosenberg · Annandale, US

Key dates

Filing date	Mar 29, 2018
Grant date	Jul 9, 2024
Priority date	—
Expiry date	Dec 26, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2750/14144
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A gene therapy treatment for alpha 1-antitrypsin (AAT) deficiency is provided comprising a plasmid or viral, e.g., an AAV, vector coding for an elastase- or cathepsin G-inhibiting, oxidation-resistant human AAT with a substitution at, for example, Met358 and/or Met351.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.